Humanized antibodies to ganglioside GM.sub.2
US6042828A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 27, 1996 |
| Grant date | Mar 28, 2000 |
| Priority date | — |
| Expiry date | Jun 27, 2016 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/867
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.